litlas
ログインアカウント作成

Marek Trněný

2006–2025 年に発表

133
論文数
23,104
被引用数
64
h 指数
125
i10 指数

被引用数

Marek Trněný の年別被引用数2000 年: 被引用 1 件2005 年: 被引用 3 件2006 年: 被引用 3 件2007 年: 被引用 14 件2008 年: 被引用 37 件2009 年: 被引用 35 件2010 年: 被引用 55 件2011 年: 被引用 67 件2012 年: 被引用 73 件2013 年: 被引用 70 件2014 年: 被引用 83 件2015 年: 被引用 87 件2016 年: 被引用 104 件2017 年: 被引用 165 件2018 年: 被引用 219 件2019 年: 被引用 712 件2020 年: 被引用 867 件2021 年: 被引用 807 件2022 年: 被引用 688 件2023 年: 被引用 513 件2024 年: 被引用 1,029 件2025 年: 被引用 528 件2026 年: 被引用 7 件2001〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,890 件、この内訳の 21.7%中国: 引用元論文 626 件、この内訳の 7.2%イタリア: 引用元論文 608 件、この内訳の 7%ドイツ: 引用元論文 605 件、この内訳の 6.9%イギリス: 引用元論文 598 件、この内訳の 6.9%フランス: 引用元論文 518 件、この内訳の 5.9%スペイン: 引用元論文 353 件、この内訳の 4%カナダ: 引用元論文 351 件、この内訳の 4%オーストラリア: 引用元論文 335 件、この内訳の 3.8%スイス: 引用元論文 310 件、この内訳の 3.5%オランダ: 引用元論文 242 件、この内訳の 2.8%日本: 引用元論文 164 件、この内訳の 1.9%
0%21.7%その他 24.4%

機関

分野

  • Medicine87.2%
  • Biochemistry, Genetics and Molecular Biology6.9%
  • Immunology and Microbiology4%
  • Computer Science0.5%
  • Materials Science0.2%
  • Chemistry0.2%
  • その他1%

トピック

  • Lymphoma Diagnosis and Treatment19.5%
  • CAR-T cell therapy research9.9%
  • Chronic Lymphocytic Leukemia Research9.6%
  • CNS Lymphoma Diagnosis and Treatment4.3%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Viral-associated cancers and disorders3.6%
  • その他49.2%

共著者

全論文

検索で開く
  1. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    著者: Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wróbel, Fritz Offner, Marek Trněný, Shang‐Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Pérez-Callejo, Linda Lundberg, James Relf, Mark R. Dixon, Emma Clark, Kathryn Humphrey, Martin Hutchings - New England Journal of Medicine 2022 被引用: 676

  2. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    著者: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 被引用: 843

  3. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    著者: Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepłuch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen - The Lancet Oncology 2022 被引用: 278

  4. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

    著者: Christian Gisselbrecht, Bertram Glaß, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, André Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg, Dávid Ma, Josette Brière, Craig H. Moskowitz, Norbert Schmitz - Journal of Clinical Oncology 2010 被引用: 1,622

  5. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

    著者: Robert Marcus, Andrew Davies, Kiyoshi Ando, Wolfgang Hiddemann, Stephen Opat, Carolyn Owen, Elizabeth H. Phillips, Randeep Sangha, Rudolf Schlag, John F. Seymour, William Townsend, Marek Trněný, Michael Wenger, Günter Fingerle‐Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann - New England Journal of Medicine 2017 被引用: 788

  6. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

    著者: Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen O. McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Judith Trotman, Wai‐Yee Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios Α. Dimopoulos - Blood 2020 被引用: 448

  7. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

    著者: John P. Leonard, Marek Trněný, Koji Izutsu, Nathan Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner, Adriana Scheliga, Grzegorz S. Nowakowski, Antonio Pinto, Francesca Re, Laura Maria Fogliatto, Phillip Scheinberg, Ian W. Flinn, Cláudia Moreira, José Cabeçadas, David Liu, Stacey Kalambakas, Pierre Fustier, Chengqing Wu, John G. Gribben, for the AUGMENT Trial Investigators - Journal of Clinical Oncology 2019 被引用: 421

  8. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

    著者: Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell - Journal of Clinical Oncology 2018 被引用: 754

  9. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia

    著者: David J. Kuter, Merlin Efraim, Jiri Mayer, Marek Trněný, Vickie McDonald, Robert Bird, Thomas Regenbogen, Mamta Garg, Zane Kaplan, Nikolay Tzvetkov, Philip Y. Choi, A.J. Gerard Jansen, Milan Kostal, Ross Baker, Jaromir Gumulec, Eun-Ju Lee, Ilona Cunningham, Isaac Goncalves, Margaret Warner, Ralph Boccia, Terry Gernsheimer, Waleed Ghanima, Olga Bandman, Regan Burns, Ann Neale, Dolca Thomas, Puneet Arora, Beiyao Zheng, Nichola Cooper - New England Journal of Medicine 2022 被引用: 138

  10. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

    著者: Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Stephanie Sasse, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Stephen M. Ansell, Kazunobu Kato, Benedetto Farsaci, Anne Sumbul, Philippe Armand, Donna Neuberg, Geraldine S. Pinkus, Azra H. Ligon, Scott J. Rodig, Margaret A. Shipp - Journal of Clinical Oncology 2018 被引用: 367

  11. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    著者: Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, Ruth Pettengell, Marek Trněný, Kevin Imrie, Dávid Ma, Devinder Gill, Jan Walewski, Pier Luigi Zinzani, Rolf A. Stahel, Stein Kvaløy, Ofer Shpilberg, Ulrich Jaeger, Mads Hansen, Tuula Lehtinen, Armando López‐Guillermo, Claudia Corrado, Adriana Scheliga, Nöel Milpied, Myriam Mendila, Michelle Rashford, Evelyn Kuhnt, Markus Loeffler - The Lancet Oncology 2006 被引用: 2,085

  12. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

    著者: Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Österborg, Marek Trněný, Lois E. Shepherd, Devinder Gill, Jan Walewski, Ruth Pettengell, Ulrich Jaeger, Pier Luigi Zinzani, Ofer Shpilberg, Stein Kvaløy, Peter de Nully Brown, Rolf A. Stahel, Nöel Milpied, Armando López‐Guillermo, Viola Poeschel, Sandra Graß, Markus Loeffler, Niels Murawski - The Lancet Oncology 2011 被引用: 811

  13. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

    著者: Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth A. Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz - Blood 2020 被引用: 169

  14. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    著者: Anas Younes, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman, Stephen M. Ansell, Philippe Armand, Michelle A. Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B. Cohen, Graham P. Collins, Kerry J. Savage, Marek Trněný, Kazunobu Kato, Benedetto Farsaci, Susan Parker, Scott J. Rodig, Margaretha G.M. Roemer, Azra H. Ligon, Andreas Engert - The Lancet Oncology 2016 被引用: 924

  15. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

    著者: Radhakrishnan Ramchandren, Eva Domingo‐Doménech, Antonio Rueda, Marek Trněný, Tatyana Feldman, Hun Ju Lee, Mariano Provencio, Christian Sillaber, Jonathon B. Cohen, Kerry J. Savage, Wolfgang Willenbacher, Azra H. Ligon, Jing Ouyang, Robert Redd, Scott J. Rodig, Margaret A. Shipp, Mariana Sacchi, Anne Sumbul, Philippe Armand, Stephen M. Ansell - Journal of Clinical Oncology 2019 被引用: 256

  16. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    著者: Meletios Α. Dimopoulos, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Sheel Patel, Aileen Cohen, Constantine S. Tam - Journal of Clinical Oncology 2023 被引用: 103

  17. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

    著者: Pier Luigi Zinzani, Jiřı́ Mayer, Christopher R. Flowers, Fontanet Bijou, Ana Carla Oliveira, Yuqin Song, Qingyuan Zhang, Michele Merli, Krimo Bouabdallah, Peter Ganly, Huilai Zhang, Roderick J. Johnson, Alejandro Martı́n, Mariano Provencio, Marek Trněný, Sam Yuen, Hervé Tilly, Edwin Kingsley, Gayane Tumyan, Sarit Assouline, Rebecca Auer, Elena V. Ivanova, Pil Kim, Sha Huang, Richard Delarue, Judith Trotman - Journal of Clinical Oncology 2023 被引用: 98

  18. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

    著者: Umberto Vitolo, Marek Trněný, David Belada, John M. Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian W. Flinn, Xiaonan Hong, Won Seog Kim, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Mikkel Z. Oestergaard, Michael Wenger, Günter Fingerle‐Rowson, Olivier Catalani, Tina Nielsen, Maurizio Martelli, Laurie H. Sehn - Journal of Clinical Oncology 2017 被引用: 424

  19. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

    著者: Martin Dreyling, Jeanette K. Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trněný, Vibeke Vergote, Ofer Shpilberg, María Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Stephan Stilgenbauer, Andrea Kerkhoff, Ron D. Jachimowicz, Melania Celli, Georg Heß, Luca Arcaini, Carlo Visco, Tom van Meerten, Stefan Wirths, Pier Luigi Zinzani, Urban Novak, Peter Herhaus, Fabio Benedetti, Kristina Sonnevi, Christine Hanoun, Matthias Hänel, Judith Dierlamm, Christiane Pott, Wolfgang Hiddemann, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster - The Lancet 2024 被引用: 136

  20. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

    著者: Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo, Raymonde Busch, Gábor Kovács, Christian Maurer, Elisabeth Lange, H. Köppler, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marek Trněný, Kirsten Fischer, Harmut Döhner, Michael Kneba, Clemens‐Martin Wendtner, Wolfgang Hiddemann, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Michael Hallek - The Lancet Oncology 2016 被引用: 622

  21. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

    著者: Éric Van Den Neste, Norbert Schmitz, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, Nöel Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Dührsen, Dávid Ma, Josette Brière, Catherine Thiéblemont, Gilles Salles, Craig H. Moskowitz, B. Glaß, Christian Gisselbrecht - Bone Marrow Transplantation 2015 被引用: 316

  22. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

    著者: Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jäger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand - Blood Advances 2023 被引用: 89

  23. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

    著者: Paolo A. Muraro, Marcelo C. Pasquini, Harold Atkins, James D. Bowen, Dominique Farge, Αthanasios Fassas, Mark S. Freedman, George E. Georges, Francesca Gualandi, Nelson Hamerschlak, Eva Havrdová, Vasilios Κ. Kimiskidis, Tomáš Kozák, Giovanni L. Mancardi, Luca Massacesi, Daniela A. Moraes, Richard A. Nash, Steven Z. Pavletic, Jian Ouyang, Montserrat Rovira, Albert Saiz, Belinda Pinto Simões, Marek Trněný, Lin Zhu, Manuela Badoglio, Xiaobo Zhong, Maria Pia Sormani, Riccardo Saccardi, for the Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group - JAMA Neurology 2017 被引用: 269

  24. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

    著者: Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepłuch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, Jennifer R. Brown - Haematologica 2020 被引用: 103